Filamentous hemagglutinin (FHA) mediates adherence and plays an important role in lower respiratory tract infections by pathogenic \textit{Bordetella}. The mature FHA proteins of \textit{B. pertussis} (Bp-FHA) and the \textit{B. bronchiseptica} (Bb-FHA) are generated by processing of the respective FhaB precursors by the autotransporter subtilisin-type protease SphB1. We have used bottom-up proteomics with differential \textsuperscript{16}O/\textsuperscript{18}O labeling and show that despite high-sequence conservation of the corresponding FhaB segments, the mature Bp-FHA (\~230 kDa) and Bb-FHA (\~243 kDa) proteins are processed at different sites of FhaB, after the Ala-2348 and Lys-2479 residues, respectively. Moreover, protease surface accessibility probing by on-column (on-line) digestion of the Bp-FHA and Bb-FHA proteins yielded different peptide patterns, revealing structural differences in the N-terminal and C-terminal domains of the Bp-FHA and Bb-FHA proteins. These data indicate specific structural variations between the highly homologous FHA proteins.

The three classical species of Gram-negative \textit{Bordetella} cause respiratory infections in mammals. While \textit{B. bronchiseptica} colonizes the nasopharynx and trachea of a broad range of mammalian hosts, such as rodents or dogs, \textit{B. pertussis} is a strictly human pathogen that causes the highly contagious respiratory disease called whooping cough or pertussis. \textit{B. parapertussis} typically infects ovines but human-adapted strains of \textit{B. parapertussis} account for up to 20\% of human whooping cough cases [1].

Introduction in the 1950s of whole-cell pertussis (wP) vaccines, composed of killed \textit{B. pertussis} cells, led to a dramatic decrease in pertussis-related mortality and incidence of the disease [2]. Safety concerns, however, led later to the replacement of the wP vaccine with the less reactogenic acellular pertussis component vaccines (aP). The latter are composed of one to five purified pertussis proteins, including chemically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and/or fimbriae of serotype 2 or 3 (FIM2, FIM3). Recent epidemiologic data show a steep increase in pertussis incidence in adolescents and adults, which is linked to the switch from the use of wP to aP vaccines in developed countries in the late 1990s [3]. While being effective in preventing clinical pertussis disease in infants, the aP vaccines appear to confer a rapidly waning protection and do not prevent bacterial colonization and transmission of the pathogen in aP-vaccinated populations [4–6].

**Abbreviations**

Bb-FHA, \textit{B. bronchiseptica} filamentous hemagglutinin; Bp-FHA, \textit{B. pertussis} filamentous hemagglutinin; ESI-FT-ICR MS, electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry; FHA, filamentous hemagglutinin; HDX, hydrogen-deuterium exchange; LC-MS/MS, liquid chromatography–tandem mass spectrometry.
The mature *B. pertussis* FHA is included in all but one of the used aP vaccines, as FHA was proposed to play an important role in bacterial adhesion and invasion of host epithelial and phagocytic cells [7]. It is a hairpin-shaped molecule (50 nm in length and approximately 4 nm in width) consisting predominantly of tandem repetitive β-strands arranged into a right-handed parallel β-helix [8]. Mature FHA or its FhbB precursor was found to mediate bacterial adhesion to a wide range of cell lines *in vitro* and FhbB appears to play a role in colonization of the lower respiratory tract in rodents, such as rats and mice [9–11]. Four different functional domains (heparin-binding, carbohydrate recognition, Arg-Gly-Asp motif, and mature C-terminal domain) of FHA were identified and implicated in interaction of mature FHA with eukaryotic cells *in vitro*. However, the roles played by these domains in Bordetella infections *in vivo* are poorly defined and remain controversial [12]. In addition to a role in bacterial adherence, the FHA protein was proposed to exert immunomodulatory signaling, inducing secretion of tolerogenic IL-10 by dendritic cells [13,14]. However, this was recently shown to be due contamination of FHA preparations by endotoxin-associated TLR2 ligands [15]. Moreover, FHA was also reported to interact with the adenylate cyclase toxin, an important Bordetella virulence factor [16,17].

Filamentous hemagglutinin of *B. pertussis* is synthesized as a 367-kDa precursor (FhaB) that is exported across the cytoplasmic membrane by the general Sec system, using an unusually long N-terminal signal peptide comprising 71 amino acid residues. The signal peptide of FhbB contains two cysteines (Cys34 and Cys35) that are necessary for post-translational cyclization of the N-terminal glutamine residue (Gln-72) of processed FhaB to a cyclic pyroglutamyl residue [18]. After removal of the signal sequence, the FhbB protein is secreted across the outer bacterial membrane by a two-partner secretion (TPS) pathway [19]. The N-terminal ‘TPS domain’ of FhbB, comprising 245 residues, initiates export across the outer membrane by interacting with the periplasmic polypeptide transport associated (POTRA) domain of FhcC, the outer membrane component of the TPS secretion pathway [20]. Translocation of FhbB proceeds in an N- to C-terminal direction, where the N terminus forms an extended hairpin through the FhcC channel and the C terminus gradually folds into a β-helix, as it emerges on the cell surface [21]. The translocated portion of FhbB is then eventually processed by the outer membrane-associated protease SphB1 to a 230-kDa mature FHA protein. The ~1300 residue-long C-terminal fragment of FhbB, called the prodomain, was recently proposed to serve as an intramolecular chaperone and appears to be rapidly degraded in bacterial periplasm [22–24].

SphB1 is a surface-exposed autotransporter protein that harbors a subtilisin-type serine protease domain. It was proposed to cleave FhbB of *B. pertussis* within the PLFETRIKFID sequence (residues 2362–2372), but the cleavage site was not identified [25]. Moreover, in SphB1-deficient (*sphB1*) strains, the FhbB precursor can still be processed to a larger FHA* protein by another, as yet unknown, protease [21,23,24].

Therefore, we used differential 16O/18O labeling and proteomics to identify the C-terminal residues of FHA proteins purified from culture supernatants of wild-type *B. pertussis* and *B. bronchiseptica* strains. The results show that despite high-sequence conservation of the processed segments, the FhbB proteins from the two species are processed at different sites. Furthermore, the N- and C-terminal domains of the two resulting FHA proteins exhibit a different surface accessibility to proteolytic cleavage.

**Material and methods**

**Bacterial strains and growth conditions**

*Bordetella pertussis* Tohama I and *Bordetella bronchiseptica* RB50 cells were grown at 37 °C on Bordet–Gengou agar (BG) supplemented with 15% defibrinated sheep blood. For liquid cultures, the bacteria were grown in Stainer–Scholte (SS) medium supplemented with 1 mg·mL⁻¹ (2,6-O-dimethyl)-β-cyclodextrin at 37 °C.

**Purification of FHA**

*Bordetella* cells were grown in 50 mL of SS medium for 8 h at 37 °C, diluted in fresh SS medium (200 mL and 1 L for *B. pertussis* and *B. bronchiseptica*, respectively) to OD₆₀₀=0.2 and cultivated for 36 or 14 h for *B. pertussis* or *B. bronchiseptica*, respectively, using a rotary shaker (160 r.p.m.) at 37 °C. The cells were spun down at 14 000 g for 25 min at 4 °C, and the supernatants were filtered through a 0.2-μm TPP Rapid Filtermax Vacuum Filtration system. The filtrates were loaded onto 5 mL bed volume of Cellulose sulfate (JNC Corporation, Japan) equilibrated with 10 mM phosphate buffer, pH 7.6 (PB), extensively washed with PB, and purified FHA proteins were eluted with PB supplemented with 700 mM NaCl. The purification procedure was performed at 4 °C. The purity of proteins was determined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS/PAGE), and the protein concentrations were determined by Bradford assay using bovine serum albumin as standard. Due to low yields, *B. bronchiseptica* FHA was concentrated by
precipitation with acetone (4:1, v/v) at −20 °C for 12 h and collected by centrifugation at 16 000 g for 10 min at 4 °C. Protein pellets were reconstituted in phosphate-buffered saline (PBS) or PBS supplemented with 4 M urea (for on-line digestion).

Protein digest and 18O stable isotope labeling

Purified FHA proteins were separated on 5% SDS/PAGE gel and stained with Coomassie brilliant blue R-250. Protein bands were excised from the gel, cut into small pieces and destained by sonication in 200 μL of Tris/HCl (pH 8.2) and 200 μL of acetonitrile (ACN). After complete destaining, the gel pieces were rinsed with 200 μL of ACN for 5 min, the liquid was discarded, and gel pieces were washed with 200 μL of H2O. Finally, the gel was washed by 200 μL of H2O/ACN (1 : 1) and dried under vacuum. Next, the gel was rehydrated in 50 μL of 10% ACN in 25 mM N-ethyl morpholine acetate buffer (pH 8.2) containing the protease. The buffer was prepared either with normal water, or doubly concentrated buffer was diluted 1:1 with H2 18O. Proteins were digested at 37 °C overnight, and the proteases used were as follows: trypsin gold (enzyme-to-substrate ratio [w/w] of 1:75), LysC, and AspN (enzyme-to-substrate ratio [w/w] of 1:50 for both). After digestion, the peptides were extracted with 100 μL of 80% ACN, 0.1% trifluoroacetic acid (TFA), dried via vacuum centrifugation, and solubilized in 100 μL of 10% ACN and 0.1% TFA. Alternatively, 50 μg samples of purified FHA was dried, solubilized in 50 mM ammonium bicarbonate buffer (pH 8.2) and digested using the same proteases as described above. In-solution digestion was carried out for 6 h. Following digestion, samples were dried and reconstituted as above. Samples from in-gel and in-solution digestion were next desalted by peptide MacroTrap (Optimize Technologies) and eluted with 150 μL of 80% ACN, 0.1% TFA. Desalted peptides were dried via vacuum centrifugation and dissolved in 50 μL of 5% ACN, 0.1% TFA (v/v) prior the LC-MS/MS analysis.

Mass spectrometry

For LC-MS/MS analyses, a capillary HPLC system (1200, Agilent Technologies, Germany) connected to an ESI source of the FT-ICR mass spectrometer (15T, SolariX XR, Bruker) was used. Peptides were separated on analytical reverse phase column (MAGIC C18 AQ, 0.2 × 150 mm, Michrom Bioresources) and separated by following gradient: 1–10% B in 1 min, 10–40% B in 50 min, where solvent A was 0.2% formic acid, 2.5% ACN, and 2.5% isopropanol, and solvent B was 0.16% formic acid in 90% ACN and 5% isopropanol. The flow rate was 4 μL·min⁻¹. ESI-FT-ICR MS was calibrated externally using arginine clusters resulting in a mass accuracy below 2 p.p.m. For peptide, mapping instrument was operated in data-dependent mode, where each MS scan was followed by up to five MS/MS collision-induced fragmentations of the most intense ions.

H/D-like mapping of FHA using immobilized endopeptidase under denaturing conditions

Digestion of FHA, with immobilized porcine pepsin A, aspergillopepsin, or rhizopuspepsin under HDX compatible conditions, was performed as described previously [26]. Briefly, the system consisted of injection and switching valves mounted with immobilized protease column, trap column (peptide MicroTrap, Optimized Technologies), and analytical column (Jupiter C18, 0.5 × 50 mm, 5 μm, 300 Å, Phenomenex), with all components immersed in an ice-water bath. Digestion and desalting (4 min) were driven by a Shimadzu LC20-AD pump isocratically delivering 0.4% formic acid at a flow rate of 100–200 μL·min⁻¹ depending on the protease column used. Gradient separation on the analytical column was carried out by an HPLC system (Agilent Technologies 1200) running at a flow rate of 15 μL·min⁻¹. Gradient elution from 5% B to 35% B in 40 min, followed by elution with 95% B, was used for separation. Solvents used were A: 0.4% formic acid and 2% ACN; and solvent B: 0.4% formic acid in 95% ACN. The outlet of the analytical column was directly connected to an electrospray ionization (ESI) source of 15T FT-ICR mass spectrometer (Bruker Daltonics). The purified Bp-FHA or Bb-FHA (300 pmol) was diluted in 0.5 M glycine/HCl buffer (pH 2.3) and injected into the column system. Alternatively, Bp-FHA, diluted 1:1 with 8 M urea (to give a final urea concentration of 4 M), or Bb-FHA, resuspended in PBS containing 4 M urea, was incubated for 30 min at 50 °C before the mixture was diluted 1:1 with 0.5 M glycine/HCl buffer (pH 2.3) and immediately injected into the chromatography system.

Data processing

Data processing was performed using Data Analysis 4.1 (Bruker Daltonics). Peak picking was carried out by FTMS and SNAP algorithms, and two mascot generic files were created for each analysis. Data from the unlabeled samples (specific protease digestion) and from on-line aspartic protease digestion were searched using local MASCOT server (MatrixScience) against a single protein database containing the sequence of FHA from B. pertussis or B. bronchiseptica with no-enzyme specificity. Peptide tolerance was set to 10 p.p.m. and fragment ion tolerance to 0.05 Da. Identified C-terminal peptides of FHA proteins were manually searched in the 18O labeled samples. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [27] partner repository with the dataset identifier PXD008664 and 10.6019/PXD008664.
Results

Purification of FHA proteins

Despite use of Bp-FHA in aP vaccines for two decades, the exact C-terminal sequence of FHA remained unknown. To identify the C-terminal residues of FHA of *B. pertussis* and of *B. bronchiseptica*, we have purified the mature forms of the two proteins from culture supernatants using a single-step affinity chromatography on Cellufine sulfate. SDS/PAGE analysis revealed that both *B. pertussis* (Bp-FHA) and *B. bronchiseptica* (Bb-FHA) FHA preparations contained the mature and the truncated forms of FHA [25], which migrated as double bands of >250 kDa (Fig. 1). Unlike the Bp-FHA preparation, which was almost homogenous, the Bb-FHA preparation contained proteolytic fragments (~130, 100 and 75 kDa) that were recognized by a polyclonal anti-FHA antibody (data not shown). This likely reflected the difficulty to purify Bb-FHA, which was obtained in about 20 times lower yields despite the use of five times larger volumes of culture supernatants. Indeed, *B. bronchiseptica* was reported to release much less FHA than *B. pertussis* [28]. The lower yield of Bb-FHA might further reflect a lower affinity for the Celluline sulfate resin, as the heparin-binding domain sequences of Bb-FHA and Bp-FHA differ importantly.

Identification of the C-terminal residue of FHA

To identify the C-terminal residues of the purified proteins, the bands corresponding to mature (FHA) and alternatively processed (FHA1) forms of the FHA proteins were excised from the SDS/PAGE gels and digested with trypsin, AspN, or LysC proteases. In parallel, the Bp-FHA and Bb-FHA preparations were digested in solution and the resulting peptides were analyzed by LC-MS/MS followed by MASCOT search. This yielded 94% and 96% coverage of the protein sequence of mature Bp-FHA and Bb-FHA, respectively (PRIDE Archive, project accession: PXD008664). The C-terminal peptides of FHA proteins were identified as peptides with masses that did not match the highly specific cleavage pattern of the used proteases (X↓-Asp/Glu for AspN; Lys↓-X for LysC; and Arg/Lys↓-X for trypsin). The C-terminal peptides of Bp-FHA1 and Bb-FHA1 were further identified by peptide mapping of the in-gel digested FHA1 bands (Fig. 1), as summarized in Table 1.

The C-terminal residue of Bp-FHA was identified as Ala2348, based on detection of two peptides that partially violated the expected cleavage pattern, namely the AspN peptide 2335DQPVAVGLEQPVA2348 and the trypsin peptide 2350NAQVADAGLAGPSAVAAPVGAADVGEPVTGQDQPVAVGLEQPVA2348. The N termini of both peptides complied with the expected cleavage rules (X↓-Asp for AspN and Arg↓-X for trypsin) but the C-terminal Ala2348 residue, followed by Thr2349 in FhaB sequence, did not, as neither AspN nor trypsin would cleave an Ala.Thr peptide bond. Similarly, the C terminus of Bp-FHA1 was identified as Ala2228, based on detection of the LysC peptide 2220RLIDDDLAL2228 and of the AspN peptide 2214DVGLEKRLIDDDLAL2228. The N termini of these peptides complied well with LysC (Arg/Lys↓-X) and AspN (X↓-Asp) cleavage rules, while the C-terminal Ala2228 residue (followed Ala2229 in FhaB sequence) could not result from cleavage of an Ala.Ala bond by LysC or AspN.

It should be noted that the 2214DVGLEKRLIDDDLAL2228 peptide contains three internal aspartate residues (D) that are possible targets for AspN cleavage, while the 2222DDALAL2228, 2224DDALAL2228, and 2225DALAL2228 fragments were not detected. This can be understood, as the tetra- and penta-peptides were too

---

**Fig. 1.** The SDS/PAGE analysis of FHA preparations purified from culture supernatants of *B. pertussis* (Bp-FHA) and *B. bronchiseptica* (Bb-FHA). The mature (FHA) and alternatively processed (FHA1) forms of FHA are indicated.
small to be trapped on the desalting column and were thus not detected by MS/MS. Moreover, AspN is rather inefficient in cutting of D-D bonds and in complete processing of all the possible cleavage sites [29].

The C-terminal residue of Bb-FHA could be identified only tentatively, as Lys2479 residue of 2446QPVVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479. This was the most C terminally located peptide detected in the AspN-generated digests of Bb-FHA. The N-terminal residue of this peptide could have resulted from an unspecific AspN-mediated cleavage on the N-terminal side of Gln2446, but AspN was unlikely to have cleaved at the N-terminal side of the Phe2480 residue, which follows Lys2479 in Bb-FHA protein. Regrettably, no other peptides allowing confirmation of the identity of the C-terminal residue of Bb-FHA were detected.

In contrast, the C-terminal residue of Bb-FHA1 was unambiguously identified by detection of the 2335DA LAAVLVNPHIF2347 and 2331LDIDDALAAVLVNPHIF2347 peptides in the AspN and tryptic digests of Bb-FHA1. Neither AspN, nor trypsin would cleave the 2347Phe.Thr2348 bond, while AspN and trypsin would generate the Asp2335 and Leu2331 N termini, respectively.

Apart from the peptides covering the analyzed Bp-FHA and Bb-FHA proteins, the detailed analysis of MS spectra revealed that both FHA preparations contained also peptides originating from Bordetellae proteins other than FHA. As shown in Table 2, four and five additional proteins were identified as contaminants of the Bp-FHA and Bb-FHA preparations. Bp-FHA contained traces of the putative phospholipid-binding protein MlaC, of the toluene tolerance protein Ttg2D, and of the S4 and S5 subunits of pertussis toxin. The Bb-FHA preparation was contaminated by adenylate cyclase toxin (CyaA), the SphB1 protease, and the Bsp22, BteA, and BopD proteins secreted by the type III secretion system.

Table 1. The C-terminal peptides of FHA and FHA1 proteins based on in-gel and in-solution digestions.

| Protease | Peptide position | Peptide sequence | M_{monoisotopic} (calculated) | M_{monoisotopic} (experimental) | Error (Δ p.p.m.) |
|----------|-----------------|-----------------|-----------------------------|-------------------------------|-----------------|
| Bordetella pertussis | FHA | AspN | 2335–2348 | DQPVVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479 | 1420.7562 | 1420.7509 | 4 |
| | FHA | trypsin | 2300–2348 | R.NAQVADAGLQPSAVAPHAGADAVGVPVTGDQVDPVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479 | 4546.3192 | 4546.3249 | 1 |
| | FHA1 | AspN | 2214–2228 | R.DVGLEKRLIDDDALAA.R.DQPVVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479 | 1641.8573 | 1641.8496 | 5 |
| | FHA1 | LysC | 2220–2228 | K.RLDIDDALAA.R.DQPVVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479 | 1000.5189 | 1000.5251 | 6 |
| Bordetella bronchiseptica | FHA | AspN | 2446–2479 | D.PQPVVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479 | 3560.0718 | 3560.0566 | 5 |
| | FHA1 | AspN | 2335–2347 | D.DALAAVLVNPHIF2347 | 1378.7608 | 1378.7514 | 7 |
| | FHA1 | trypsin | 2331–2347 | R.LDIDDALAAVLVNPHIF2347 | 1834.9828 | 1834.9818 | 1 |

Table 2. The overall protein content in the Bp-FHA and Bb-FHA preparations.

| Protein | MW (kDa) | Isoelectric point (pI) |
|---------|---------|------------------------|
| Bp-FHA  | Filamentous hemagglutinin | 367 | 9.2 |
| Pertussis toxin subunit 4 | 14 | 9.2 |
| Pertussis toxin subunit 5 | 13 | 5.4 |
| Toluene tolerance protein Ttg2D | 20 | 9.2 |
| Probable phospholipid-binding protein mlaC | 21 | 9.2 |
| Bb-FHA  | Filamentous hemagglutinin | 372 | 8.7 |
| Adenylate cyclase toxin | 178 | 4.4 |
| SphB1 protease | 87 | 9.7 |
| T3SS protein BopD | 32 | 6.4 |
| T3SS protein Bsp22 | 22 | 7.2 |
| T3SS protein BteA | 69 | 5.0 |

To corroborate the identification of the C-terminal residues of Bp-FHA and Bb-FHA proteins, we performed differential stable 18O isotope labeling. The method is based on protease-catalyzed 18O replacement of two 16O atoms on the carboxyl of a newly liberated C-terminal residue of a peptide that is generated by proteolytic cleavage of a protein in the presence of isotopic water (H218O) [30]. As the carboxyl of the preexisting C-terminal residue of the digested protein remains unlabeled, the resulting mass difference between the labeled and the unlabeled peptide ions permits the identification of the peptide that contains the C-terminal residue of the given protein.

As shown in Fig. 2, the isotope envelopes of the 2335DQPVVAVGLEQPAAAVRVAPPAVALPRPLFETRIK2479 and 2214DVGLEKRLIDDDALAAVLVNPHIF2347 peptide peaks in the 18O-labeled AspN digests of the Bp-FHA and of the Bp-FHA1 proteins were identical to that observed for the same peptides.
in nonlabeled digests. The same was true for the \(2446\text{QPVAVGLEQPVA}2448\) and \(2335\text{DALAAVLNPHIF}2347\) peptides derived from Bb-FHA and Bb-FHA1 (Fig. 2). In contrast, the isotope envelopes of all other peptides in the \(^{18}\text{O}\)-labeled AspN digests of Bp-FHA/Bp-FHA1 and Bb-FHA/Bb-FHA1 proteins exhibited the expected shifts to ‘double peaks’. These comprised strikingly enhanced intensities of the monoisotopic masses of the \(^{18}\text{O}\)-labeled peptides, as documented in Fig. 2 for the internal \(2279\text{DALASLASL}2288\) and \(1086\text{DLQAGRSMTLGTVD}T\text{T}G_{1102}\) peptides from the Bp-FHA and Bb-FHA proteins. These data thus fully confirmed that Ala\(_{2348}\) and Ala\(_{2228}\) were the C-terminal residues of

Fig. 2. Isotope profiles of the C-terminal peptides of FHA and FHA\(_1\) after enzymatic digestion of Bp-FHA (upper panel) and Bb-FHA (lower panel) with AspN in the presence of normal H\(_2\)O (unlabeled) and 50\% \(^{18}\text{O}\) water (\(^{18}\text{O}\)-labeled).

 shifts to ‘double peaks’. These comprised strikingly enhanced intensities of the monoisotopic masses of the \(^{18}\text{O}\)-labeled peptides, as documented in Fig. 2 for the internal \(2279\text{DALASLASL}2288\) and \(1086\text{DLQAGRSMTLGTVD}T\text{T}G_{1102}\) peptides from the Bp-FHA and Bb-FHA proteins. These data thus fully confirmed that Ala\(_{2348}\) and Ala\(_{2228}\) were the C-terminal residues of
Bp-FHA and of Bp-FHA1, while Lys2479 and Phe2347 were the C-terminal residues of Bb-FHA and of Bb-FHA1, respectively.

### Mapping of FHA surface accessibility using immobilized endopeptidase columns

To gain insight into the specific sequence-structure relationships of the Bp-FHA and Bb-FHA proteins, we performed an on-line digestion of the two proteins on immobilized acid protease columns connected to an LC-MS/MS analyzer. This instrumental setup comprises a continuous workflow system that is commonly employed for analysis of protein hydrogen/deuterium exchange (HDX) by mass spectrometry [26]. The main advantage of this protocol is the rapidity of digestion and the absence of sample handling. This minimizes sample loss and unwanted protein modifications that may occur during lengthy digestions in typical proteomic protocols.

Initial experiments with on-line digestion of Bp-FHA on an immobilized pepsin column at low pH (2.3) gave low peptide yields with sequence coverage of only 21% (data not shown). Remarkably, the recovered peptides predominantly originated from the C terminus of the mature Bp-FHA protein (residues 1600–2350), indicating that the C-terminal segment of Bp-FHA is much more susceptible to protease digestion than its N-terminal segment that exhibits a compact parallel β-helical fold [8,29]. To increase the sequence coverage of the N-terminal portion of FHA [19], the on-line digestion was performed in the presence of denaturing agents, such as 3 m guanidine chloride or 4 m urea. These conditions usually do not denature proteins, but induce a partial destabilization of compact protein folds. Moreover, such concentrations of denaturing agents do not affect the cleavage efficiency of the immobilized proteases [26]. Different protease columns (pepsin, nepenthesin-1, aspergillopepsin, and rhizopuspepsin) along with different times and temperatures of digestion were also tested. Preliminary experiments showed that the best results were obtained on columns with immobilized pepsin proteases and operated and at flow rates of 100–200 μL·min⁻¹ at 50 °C.

The on-line digest peptide map acquired under such conditions covered near completely the sequence of Bp-FHA, starting from the N-terminal pyroglutamate residue 72, up to the C-terminal Ala2348 residue (Fig. 3). In

![Graph showing surface accessibility of Bp-FHA and Bb-FHA](image)

**Fig. 3.** Surface accessibility of Bp-FHA and Bb-FHA probed by on-column (on-line) digestion. The FHA proteins were incubated in the presence of 4 m urea at 50 °C for 30 min and loaded on immobilized protease columns directly coupled to LC-MS/MS analyzer. Frequency of the appearance of individual residues in the covered sequence is plotted as the number of unique peptides against the protein sequence. The data represent the aggregate result obtained from the on-line digests using rhizopuspepsin, pepsin A, and aspergillopepsin columns.
contrast, the sequence coverage of the on-line digest of Bb-FHA was less complete (Fig. 3). The on-line digestion was performed for a limited time under semidenaturing conditions, using proteases that mostly cleave C terminally to frequently occurring small hydrophobic residues. Therefore, the numbers of generated unique peptides, comprising a given residue of the FHA protein, reflect the accessibility of the corresponding segment to proteolytic cleavage and the compactness of its structure. The quantitative analysis of the peptide maps revealed a striking difference in the overall distribution of unique peptides that were generated by on-line digestion of the Bp-FHA and Bb-FHA proteins (Fig. 3). Irrespective of the protease used, importantly higher number of unique peptides was recovered from the C-terminal segment of Bp-FHA, than from its N-terminal segment, thus indicating a loosened conformation of the C-terminal segment of Bp-FHA. In contrast, the C-terminal segment of Bb-FHA yielded disproportionally low numbers of unique peptides, which is indicative of a tightly packed structure. In contrast, substantially higher numbers of unique peptides were generated from the N-terminal segment of Bb-FHA, indicating its loosened structure (Fig. 3). This would go well with the fact that the N-terminal segment of Bb-FHA is about 131 residues longer than the corresponding segment of Bp-FHA. On the other hand, the C-terminal processing of the Bp-FHA and Bb-FHA proteins occurred at sites 21 residues apart within a segment of very high-sequence homology of the Bp-FHA and Bb-FHA proteins (Fig. 4).

Discussion

Release of many proteins and peptides from eukaryotic and prokaryotic cells involves proteolytic maturation of the secreted protein precursors. Production of the mature FHA protein of Bordetella pertussis involves processing of the 367-kDa FhaB precursor, from which the bacterial surface-anchored autotransporter subtilisin-type protease SphB1 removes the 130-kDa C-terminal prodomain [23,31,32]. Here, we have defined the C-terminal residues of the mature and alternatively processed forms of FHA from the closely related B. pertussis and B. bronchiseptica species.

Up to now, the C terminus of the mature FHA protein could not be accurately identified and it was only estimated by mass determination of purified B. pertussis FHA. The reported MALDI-TOF analysis indicated that mature Bp-FHA may arise from FhaB processing within the PLFETRIKFID sequence between residues 2362 and 2372 [25]. By analogy, processing of Bb-FHA was predicted to occur between residues 2472 and 2482 of Bb-FhaB. However, insufficient accuracy of mass determination of the 230-kDa protein by MALDI-TOF MS did not permit identification of its C-terminal residue. The here-employed digest-based mapping by high-resolution FTICR-MS, combined with postdigestion $^{18}$O-labeling analysis, yielded unambiguous identification of the C-terminal residues of the various forms of the FHA protein (Fig. 4). Firstly, the C-terminal residues of peptides that did not match the cleavage specificity of the used proteases indicated that the Ala2348 and Ala2228 were the bona fide C-terminal residues of the mature Bp-FHA/Bp-FHA$_1$ proteins. The Lys2479 and Phe2347 residues were then identified as the respective C-terminal residues of the Bb-FHA/Bb-FHA$_1$ proteins. Indeed, the molecular masses of peptides comprising these residues remained unchanged upon postdigestion $^{18}$O-exchange labeling of the carboxyls of the C-terminal residues of peptides that were newly generated by in vitro protease digestion in H$_2$O. This confirmed the correct assignment of the C-terminal residues.

Mazar and Cotter (2006) have previously shown that the SphB1 protease is involved in proteolytic maturation of FhaB to FHA and FHA$_1$ both in B. pertussis and in B. bronchiseptica. Moreover, the processed regions of the FhaB precursors from the two species exhibit a very high degree of sequence identity (Fig. 4) and the SphB1 proteases of the two species are themselves identical to 98%. It is, therefore, intriguing that processing of the FhaB proteins from the two species was found to occur at quite different sites located 21 residues apart within the same highly conserved segment of FhaB. Moreover, the processing step involved cleavage of peptide bonds between rather different pairs of residues. The bond between a small hydrophobic Ala2348 and a small hydrophilic Thr2349 residue was cleaved in Bp-FhaB, while processing of the Bb-FhaB protein resulted from cleavage of the bond between a positively charged Lys2479 and a bulky aromatic Phe2480 residue. As a result, the C-terminal segment of the mature Bb-FHA is extended by 21 residues, compared to mature Bp-FHA. Similarly, the C-terminal sequences of Bp-FHA$_1$ and Bb-FHA$_1$ differ by 9 residues.

Albeit unlikely, it cannot be excluded that upon SphB1-mediated cleavage the C termini of FHA may be further processed by some other secreted bacterial proteases. Alternatively, these unexpected results may indicate that the substrate specificities of the highly conserved SphB1 proteases of the two bacterial species may differ. The SphB1 protease, indeed, belongs to a superfamily of subtilisin-like proteases that possess rather broad substrate specificity. This is largely
determined by interactions of the P4-P1 residue side chains in the binding pocket of the enzyme, which enables the cleavage of peptide bonds on the C-side of aliphatic or aromatic amino acid residues [33]. A closer look on the P4-P1 residues of Bp-FHA (QPVA2348) and Bp-FHA1 (DALA2228) reveals a certain analogy between their C-terminal sequences, in terms of side chain properties, indicating that Bp-FhaB is processed by SphB1 with a defined substrate specificity. In contrast, the C-terminal sequences of Bb-FHA (TRIK2479) and Bb-FHA1 (PHIF2347) are rather distinct and do not appear to share any similarity, even though the C-terminal residue of Bb-FHA1 complies with the substrate specificity of subtilisin-like proteases. However, the C-terminal Lys2479 residue of Bb-FHA does not match the substrate specificity of a subtilisin type of protease. It thus remains to be determined if the Bb-SphB1 has a broader substrate specificity than Bp-SphB1, or another as yet unknown protease participates in the final processing of the Bb-FhaB precursor.

Even though the Bp-FHA and Bb-FHA proteins are highly homologous (90% identity) and appear to be
functionally interchangeable between *B. pertussis* and *B. bronchiseptica* [34], our data show that the C termini of mature FHA proteins differ by 21 amino acid residues. The here observed difference in the processing and protease susceptibility of the C-terminal segments of the two proteins is intriguing, as the mature C-terminal domain of FHA was proposed to play an important role in adherence and virulence of *Bordetella* [11,24,31,34]. *B. pertussis* is a fully human-adapted pathogen, while *B. bronchiseptica* infects a broad variety of mammals. It will, hence, be important to determine whether the difference in FhaB processing in the two bacterial species plays a role in the biological activity of mature FHA proteins.

**Acknowledgement**

We would like to thank Petr Pompach for help with MS measurements. Access to the mass spectrometry facility was enabled through the MEYS/EU projects CZ.1.05/1.1.00.02.0109 and LM2015043 CIISB. This work was supported by the projects LM2015064 (Czech National Node to the European Infrastructure for Translational Medicine) from the Ministry of Education, Youth and Sports of the Czech Republic. The project was supported by the projects LQ1604 (PM), GA18-20621S (PS), and GA15-11851S (LB) are also acknowledged.

**Author contributions**

DJ measured and analyzed the data, PM performed and evaluated the on-line digests, LB and PS designed the project, and LB, DJ, and PS wrote the manuscript.

**Conflict of interest**

The authors declare no conflict of interest.

**References**

1. Diavatopoulos DA, Cummings CA, Schouls LM, Brinig MM, Relman DA and Mooi FR (2005) Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of *B. bronchiseptica*. *PLoS Pathog* 1, 0373–0383.

2. Mattoo S and Cherry JD (2005) Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. *Clin Microbiol Rev* 18, 326–382.

3. Klein NP (2014) Licensed pertussis vaccines in the United States: history and current state. *Hum Vaccines Immunother* 10, 2684–2690.

4. Warfel JM and Edwards KM (2015) Pertussis vaccines and the challenge of inducing durable immunity. *Curr Opin Immunol* 35, 48–54.

5. Tarot SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA et al. (2013) Waning immunity to pertussis following 5 doses of DTaP. *Pediatrics* 131, e1047–e1052.

6. Witt MA, Arias L, Katz PH, Truong ET and Witt DJ (2013) Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. *Clin Infect Dis* 56, 1248–1254.

7. Hazenbos WLW, Van den Berg BM, Van’t Wout JW, Mooi FR and Van Furth R (1994) Virulence factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by human monocytes. *Infect Immun* 62, 4818–4824.

8. Makhov AM, Hannah JH, Brennan MJ, Trus BL, Kocsis E, Conway JF, Wingfield PT, Simon MN and Steven AC (1994) Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19-residue repeat motif rich in beta strands and turns. *J Mol Biol* 241, 110–124.

9. Cotter PA, Yuk MH, Mattoo S, Akerley BJ, Boschwitz J, Relman DA and Miller JF (1998) Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. *Infect Immun* 66, 5921–5929.

10. Mattoo S, Miller JF and Cotter PA (2000) Role of Bordetella bronchiseptica fimbriae in tracheal colonization and development of a humoral immune response. *Infect Immun* 68, 2024–2033.

11. Inatsuka CS, Julio SM and Cotter PA (2005) Bordetella filamentous hemagglutinin plays a critical role in immunomodulation, suggesting a mechanism for host specificity. *Proc Natl Acad Sci USA* 102, 18578–18583.

12. Villarino Romero R, Osicka R and Sebo P (2014) Filamentous hemagglutinin of Bordetella pertussis: a key adhesin with immunomodulatory properties? *Future Microbiol* 9, 1339–1360.

13. Dirix V, Mielcarek N, Debrise AS, Willery E, Alonso S, Versheure V, Mascart F and Locht C (2014) Human dendritic cell maturation and cytokine secretion upon stimulation with Bordetella pertussis filamentous haemagglutinin. *Microbes Infect* 16, 562–570.

14. McGuirk P and Mills KHG (2002) Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. *Trends Immunol* 23, 450–455.

15. Villarino Romero R, Hasan S, Faé K, Holubova J, Geurtjen S, Schwarzer M, Wiertsema S, Osicka R, Poolman J and Sebo P (2016) Bordetella pertussis filamentous hemagglutinin itself does not trigger anti-
inflammatory interleukin-10 production by human dendritic cells. *Int J Med Microbiol* **306**, 38–47.

16 Zaretzky FR, Gray MC and Hewlett EL (2002) Mechanism of association of adenylate cyclase toxin with the surface of Bordetella pertussis: a role for toxin-filamentous haemagglutinin interaction. *Mol Microbiol* **45**, 1589–1598.

17 Perez Vidakovics MLA, Lamberti Y, Van Der Pol WL, Yantorno O and Rodriguez ME (2006) Adenylate cyclase influences filamentous haemagglutinin-mediated attachment of Bordetella pertussis to epithelial alveolar cells. *FEMS Immunol Med Microbiol* **48**, 140–147.

18 Lambert-Buisine C, Willery E, Locht C and Jacob-Dubuisson F (1998) N-terminal characterization of the Bordetella pertussis filamentous haemagglutinin. *Mol Microbiol* **28**, 1283–1293.

19 Clantin B, Hodak H, Willery E, Locht C, Jacob-Dubuisson F and Villeret V (2004) The crystal structure of filamentous hemagglutinin secretion domain and its implications for the two-partner secretion pathway. *Proc Natl Acad Sci USA* **101**, 6194–6199.

20 Clantin B, Delattre A-SS, Rucktooa P, Saint N, Méli AC, Locht C, Françoise J-D and Villeret V (2007) Structure of the membrane protein FhaC: a member of the Omp85-TpsB transporter superfamily. *Science* **317**, 957–961.

21 Mazar J and Cotter PA (2006) Topology and maturation of filamentous haemagglutinin suggest a new model for two-partner secretion. *Mol Microbiol* **62**, 641–654.

22 Renaud-Mongénie G, Cornette J, Mielcarek N, Menozzi FD and Locht C (1996) Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. *J Bacteriol* **178**, 1053–1060.

23 Noël CR, Mazar J, Melvin JA, Sexton JA and Cotter PA (2012) The prodomain of the Bordetella two-partner secretion pathway protein FhaB remains intracellular yet affects the conformation of the mature C-terminal domain. *Mol Microbiol* **86**, 988–1006.

24 Melvin JA, Scheller EV, Noël CR and Cotter PA (2015) New insight into filamentous hemagglutinin secretion reveals a role for full-length FhaB in Bordetella virulence. *MBio* **6**, e01189–15.

25 Coutte L, Antoine R, Drobecq H, Locht C and Jacob-Dubuisson F (2001) Subtilisin-like auto transporter serves as maturation protease in a bacterial secretion pathway. *EMBO J* **20**, 5040–5048.

26 Kadék A, Mrazek H, Halada P, Rey M, Schriemer DC and Man P (2014) Aspartic protease nepenthesin-1 as a tool for digestion in hydrogen/deuterium exchange mass spectrometry. *Anal Chem* **86**, 4287–4294.

27 Vizcaíno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavídas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternet T et al. (2016) 2016 update of the PRIDE database and its related tools. *Nucleic Acids Res* **44**, D447–D456.

28 Jacob-Dubuisson F, Kehoe B, Willery E, Reveneau N, Locht C and Relman DA (2000) Molecular characterization of Bordetella bronchiseptica filamentous haemagglutinin and its secretion machinery. *Microbiology* **146**, 1211–1221.

29 Giansanti P, Tsatsianu L, Low TY and Heck AJR (2016) Six alternative proteases for mass spectrometry-based proteomics beyond trypsin. *Nat Protoc* **11**, 993–1006.

30 Ye X, Luke B, Andresson T and Blonder J (2009) 18O stable isotope labeling in MS-based proteomics. *Brief Funct Genomic Proteomic* **8**, 136–144.

31 Coutte L, Alonso S, Reveneau N, Willery E, Quatannens B, Locht C and Jacob-Dubuisson F (2003) Role of adhesin release for mucosal colonization by a bacterial pathogen. *J Exp Med* **197**, 735–742.

32 Coutte L, Willery E, Antoine R, Drobecq H, Locht C and Jacob-Dubuisson F (2003) Surface anchoring of bacterial subtilisin important for maturation function. *Mol Microbiol* **49**, 529–539.

33 Siezen RJ and Leunissen JA (1997) Subtilases: the superfamily of subtilisin-like serine proteases. *Protein Sci* **6**, 501–523.

34 Julio SM, Inatsuka CS, Mazar J, Dieterich C, Relman DA and Cotter PA (2009) Natural-host animal models indicate functional interchangeability between the filamentous haemagglutinins of Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but not the RGD motif, during infection. *Mol Microbiol* **71**, 1574–1590.